Borrelia burgdorferi Antibody, IgG by Immunoblot
Also known as: LYME G WB
Use
The test confirms the presence of antibodies against Borrelia burgdorferi, the bacterium that causes Lyme disease, in patients. It is a second-tier test used more than four weeks after the onset of symptoms, following a first-tier screening. A positive result suggests an infection consistent with Lyme disease.
Special Instructions
This test should be ordered only if the first-tier screening tests for Lyme disease are positive or equivocal. It is not recommended for samples obtained less than four weeks after symptom onset.
Limitations
A negative result implies no detectable antibodies against Borrelia burgdorferi, which does not support a Lyme disease diagnosis. False negatives can occur, particularly in early or untreated cases. The test is not recommended for diagnosing neuroborreliosis or chronic Lyme disease, especially using IgM immunoblot. Clinical correlation is essential for diagnosis as lab results need to be interpreted in the context of the patient's clinical presentation.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Qualitative Immunoblot)
Biomarkers
LOINC Codes
- 6320-6
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.1 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection and transfer to an ARUP Standard Transport Tube.
Causes for Rejection
CSF or plasma. Contaminated, heat-inactivated, severely hemolyzed, severely lipemic, and severely icteric specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |